PAR.ASX Trading Halt Pending Phase 3 Clinical Trial Results
Key points
- Trading halt requested by Paradigm Biopharmaceuticals
- Halt in effect until announcement release or 23 Sep 2026
- Halt due to pending Phase 3 Clinical Trial results
- No other information necessary to inform the market
Full summary
Paradigm Biopharmaceuticals Limited (PAR) has requested a trading halt on its securities pending the release of an announcement regarding the Interim Analysis results for its Phase 3 Clinical Trial. The trading halt will remain in effect until the earlier of the release of the announcement or the commencement of trading on Wednesday, 23 September 2026. The company is not aware of any reason why the trading halt should not be granted and does not believe any other information is necessary to inform the market.
Sign in for more about this company, including guidance changes and other insights.
Sign in